Eldelumab
Eldelumab
Eldelumab (pronounced el-de-lu-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases. It is an experimental drug that has been studied for its potential to modulate the immune system.
Etymology
The name "Eldelumab" follows the INN naming convention for monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the prefix "Eld-" does not have a specific meaning.
Mechanism of Action
Eldelumab works by binding to a specific target on immune cells, known as the IL-7 receptor. By blocking this receptor, Eldelumab can potentially reduce the activity of the immune system and alleviate symptoms of autoimmune diseases.
Clinical Trials
Eldelumab has been tested in several clinical trials for conditions such as rheumatoid arthritis and psoriasis. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Interleukin-7 receptor
- Clinical trial
- Rheumatoid arthritis
- Psoriasis
External links
- Medical encyclopedia article on Eldelumab
- Wikipedia's article - Eldelumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski